Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Sell
15
CELU Quote, Financials, Valuation and Earnings
Last price:
$1.30
Seasonality move
:
-11.38%
Day range:
$1.25 - $1.33
52-week range:
$1.00 - $4.35
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.77x
P/B ratio:
10.68x
Volume:
23.3K
Avg. volume:
71.2K
1-year change:
-40.09%
Market cap:
$36.8M
Revenue:
$54.2M
EPS (TTM):
-$3.33
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Celularity, Inc. has 1823.08% upside to fair value with a price target of -- per share.
CELU vs. S&P 500
-
Over the past 5 trading days, Celularity, Inc. has overperformed the S&P 500 by 5.78% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Celularity, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Celularity, Inc. revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Celularity, Inc. reported revenues of $5.3M.
Earnings Growth
-
Celularity, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Celularity, Inc. reported earnings per share of -$0.88.
Enterprise value:
103.5M
EV / Invested capital:
--
Price / LTM sales:
0.77x
EV / EBIT:
--
EV / Revenue:
2.55x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-12.75x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$13.2M
Return On Assets:
-50.01%
Net Income Margin (TTM):
-198.75%
Return On Equity:
-1606.74%
Return On Invested Capital:
-126.17%
Operating Margin:
-244.13%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $14.8M | $48.2M | $40.6M | $9.3M | $5.3M | |
| Gross Profit | -$6.3M | $22.6M | $13.2M | $3.5M | -$444K | |
| Operating Income | -$97.4M | -$39.9M | -$48.7M | -$11.5M | -$12.9M | |
| EBITDA | -$87.9M | -$31.6M | -$41.4M | -$9.6M | -$11.1M | |
| Diluted EPS | -$10.18 | -$1.56 | -$3.33 | -$0.73 | -$0.88 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $91.3M | $63.1M | $16.5M | $14.5M | $10.6M | |
| Total Assets | $448.3M | $437.1M | $157.2M | $128.8M | $114.2M | |
| Current Liabilities | $29.2M | $69.2M | $84.6M | $76.2M | $65.3M | |
| Total Liabilities | $352.1M | $272.9M | $126.9M | $111.6M | $134.3M | |
| Total Equity | $96.2M | $164.2M | $30.2M | $17.3M | -$20.1M | |
| Total Debt | $31.1M | $27.9M | $26.1M | $26.5M | $62.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$63.9M | -$12.3M | -$6.6M | -$144K | -$4.2M | |
| Cash From Investing | -$4.2M | $1.5M | -$1.6M | -$35K | -- | |
| Cash From Financing | $25.8M | $6M | $8.1M | -$79K | $3.5M | |
| Free Cash Flow | -$68.2M | -$13M | -$8.1M | -$179K | -$4.2M | |
CELU
Sector
Market Cap
$36.8M
$28.3M
Price % of 52-Week High
29.89%
51.99%
Dividend Yield
0%
0%
Shareholder Yield
-9.49%
-1.59%
1-Year Price Total Return
-40.09%
-17.41%
Beta (5-Year)
0.801
0.495
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.22
200-day SMA
Sell
Level
$2.12
Bollinger Bands (100)
Sell
Level
1.4 - 2.76
Chaikin Money Flow
Sell
Level
-123.7K
20-day SMA
Sell
Level
$1.37
Relative Strength Index (RSI14)
Sell
Level
42.07
ADX Line
Sell
Level
18.98
Williams %R
Neutral
Level
-38.2979
50-day SMA
Sell
Level
$1.65
MACD (12, 26)
Sell
Level
-0.14
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Neutral
Level
58.6K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.277)
Sell
CA Score
(Annual)
Level (-2.9281)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (6.472)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Celularity, Inc. is a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert Joseph Hariri Gordon in 2016 and is headquartered in Florham Park, NJ.
Stock Forecast FAQ
In the current month, CELU has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CELU average analyst price target in the past 3 months is --.
-
Where Will Celularity, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Celularity, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Celularity, Inc.?
Analysts are divided on their view about Celularity, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Celularity, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is Celularity, Inc.'s Price Target?
The price target for Celularity, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CELU A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Celularity, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CELU?
You can purchase shares of Celularity, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Celularity, Inc. shares.
-
What Is The Celularity, Inc. Share Price Today?
Celularity, Inc. was last trading at $1.30 per share. This represents the most recent stock quote for Celularity, Inc.. Yesterday, Celularity, Inc. closed at $1.30 per share.
-
How To Buy Celularity, Inc. Stock Online?
In order to purchase Celularity, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CELU Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CELU
Sector
P/E ratio
--
24.24x
PEG ratio
0.00x
-0.01x
P/B ratio
10.68x
1.84x
Price / LTM sales
0.77x
1.60x
Growth Metrics
CELU
Sector
Revenue growth
-43.16%
4.6%
Earnings growth
-19.56%
10.71%
Revenue (5-year growth)
--
6.45%
Earnings forecast
--
-$0.19
Profitability
CELU
Sector
Profitability FY 2024
$31.3M
$3.5M
Return on invested capital
-126.17%
-32.04%
Return on assets
-50.01%
-28.44%
Return on equity
-1606.74%
-38.09%
Earnings Date
Last Earnings Date
Aug
18
Next Earnings Date
Jan
10
Estimated Next Earnings Date
Apr
11
Balance Sheet
CELU
Sector
Total cash
$120K
$26.1M
Short term investments
--
$25.7M
Total assets
$314.1M
$76.4M
Long term debt
$62.5M
$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
65
RGC alert for Jan 9
Regencell Bioscience Holdings Ltd. [RGC] is up 10.55% over the past day.
Sell
50
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
